CPH2 Signs MOU with Siemens to Scale Up Hydrogen Electrolyser Production

CPH2 signs non-binding MOU with Siemens to scale up its membrane-free electrolyser production, gaining industrial expertise and market access.

24 March 2026by Joshua Thompson5 min read19 views

This article covers information on Clean Power Hydrogen.

LON:CPH2

CPH2’s non-binding MOU with Siemens: what’s been announced

Clean Power Hydrogen (AIM: CPH2) has signed a non-binding Memorandum of Understanding with Siemens plc. The goal is clear: help CPH2 scale manufacturing of its Membrane-Free Electrolyser (MFE) technology and sustain its technology lead in clean hydrogen production. Both parties intend to move to a legally binding agreement, with further updates promised “in due course”.

In plain English, this is a structured handshake with a big industrial partner. It lays out how Siemens could support CPH2 across process, automation, customer introductions and go-to-market efforts, but it’s not yet a firm contract.

Partner	Siemens plc
Agreement type	Non-binding Memorandum of Understanding (MOU)
Focus	Scale-up of CPH2’s Membrane-Free Electrolyser (MFE) production and technology leadership
Planned Siemens support	Process and automation, customer introductions, marketing, 24/7 technical support, training, joint product and process development, go-to-market strategies
Status	Discussions ongoing; intent to conclude a legally binding agreement
Ticker	LSE: CPH2
Financials/terms	Not disclosed

What the MOU actually covers (and why it matters)

The CEO, Jon Duffy, set out a broad collaboration canvas with Siemens that spans:

Enhanced process and automation – industrialising build and test, a key bottleneck in electrolyser scale-up.
Customer introduction and marketing – tapping Siemens’ enterprise relationships to open doors.
24/7 technical support and training – a service backbone that large buyers increasingly expect.
Joint product and process development – co-developing improvements that can lower costs and lift reliability.
Go-to-market strategies – aligning on how to sell, deliver and service at scale.

For a company looking to move from clever kit to high-volume deployment, these are the right levers. If executed, they can shorten time-to-market, improve manufacturability, and help win bigger, stickier customers who value lifetime support over one-off kit.

Why Siemens’ involvement could be a catalyst

Siemens brings deep expertise in automation, controls and industrial systems integration. For electrolyser makers, the hard yards are less about the lab breakthrough and more about repeatable, quality-assured production and field performance. Siemens’ toolkit squarely targets those pain points.

There is also a brand and channel effect. Being introduced to Siemens’ customer base and co-marketing can accelerate commercial traction, especially where buyers need comfort around uptime, service and spare parts. The mention of 24/7 technical support and training hints at building the aftersales infrastructure that institutional buyers screen for.

Share𝕏 in

Investing
Polar Capital Technology Trust Reports 102% NAV Growth in Stellar Fiscal Year
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Investing

Tagged

Last updated

5 July 2026

Star Rating

No ratings yet

Potential upside if it moves to a binding deal

Faster ramp in MFE manufacturing with fewer teething issues.
Lower execution risk on complex projects through Siemens’ systems know-how.
Improved route to market and credibility in competitive tenders.
Scope for joint development to push down the Levelised Cost of Hydrogen (LCOH) over the product life.

The caveat: an MOU is not a contract

It’s important to stress this is non-binding. There are no disclosed commitments, minimum volumes, revenue guarantees or timelines. The RNS does not provide any financial terms, target capacities, or dates for a definitive agreement.

Until a binding contract is signed, investors should treat this as strategic intent rather than booked business. Execution risk remains – scope could narrow, timings could slip, or the parties might not reach final terms.

What’s not disclosed (and why you should care)

Commercial terms – not disclosed. We don’t know how costs, revenues or IP will be shared.
Timeline to binding agreement – not disclosed. “In due course” leaves the calendar open.
Manufacturing targets – not disclosed. No stated capacity, cost or yield milestones.
Order pipeline impact – not disclosed. No indication of immediate orders or backlog conversion.
Funding requirements – not disclosed. Scaling production and service usually needs capital; there’s no update here.

Quick primer: CPH2 and its MFE technology

CPH2 has developed IP-protected Membrane-Free Electrolyser technology to produce high purity hydrogen and above medical-grade purity oxygen. The company highlights a decade of research and development and global patents behind the system. Its strategic objective is to deliver the lowest lifetime Levelised Cost of Hydrogen in the market at this scale. LCOH bundles capex, opex, efficiency and lifetime into a single cost per kilogram – the key yardstick for competitiveness.

CPH2 is listed on AIM under LSE: CPH2. Beyond that, the RNS does not provide financials or operational run-rates.

Why this announcement moves the story forward

Clean hydrogen is shifting from demonstrators to scaled assets, and buyers now prioritise bankability, serviceability and integration. This MOU targets those exact proof points. If Siemens helps CPH2 industrialise, it could translate R&D edge into commercial edge.

On the flip side, the market has seen plenty of MOUs that never matured. The difference-maker will be how quickly both parties define scope, governance and KPIs in a binding agreement – and how that ties to orders and revenue.

What to watch next from here

Binding agreement RNS – look for clear scope, term, milestones and any financial commitments.
Manufacturing metrics – named capacity targets, cycle-time reductions, or yield improvements.
Commercial traction – customer introductions converting into signed projects or framework agreements.
Service build-out – details on 24/7 support, training programmes and spare-parts logistics.
Capital plan – any funding, capex, or working capital needs to support scale-up.

My take for investors

Net positive. Siemens’ prospective involvement is exactly the kind of industrial muscle CPH2 needs to scale its Membrane-Free Electrolyser platform and support the ambition to drive down LCOH. The breadth of the discussion – from automation to go-to-market and 24/7 support – reads well.

However, it’s an MOU. Without binding terms, timelines or financials, this is not investment-grade certainty. Near-term share price moves may track sentiment and anticipation; the durable re-rating requires a definitive agreement and, ideally, visible order flow that leans on Siemens’ channels.

Bottom line: promising strategic step, credible potential partner, but patience and proof will be required. Watch for the next RNS to see whether intent becomes execution.